The pharmaceutical industry, long defined by the grueling, multi-billion-dollar process of molecule discovery and clinical trials, is currently undergoing a structural pivot. For decades, the primary objective of major life sciences firms has been the development of novel chemical or biological entities. However, a burgeoning cohort of health-tech innovators is now arguing that the next frontier of medical progress does not lie in the lab alone, but in the digital architecture that surrounds the patient. Or Shoval, Chief Executive Officer of Remepy, encapsulates this transition with a provocative thesis: the next major breakthrough in pharma will not necessarily come from discovering new molecules, but from making existing drugs significantly more effective through software.
This perspective marks a shift toward "digital therapeutics" and "software-as-a-drug" models, where the efficacy of a pharmaceutical intervention is amplified by behavioral modification, data-driven feedback loops, and personalized digital interventions. As the industry faces stagnating research and development (R&D) returns—where the average cost to bring a new drug to market has ballooned to over $2 billion—the integration of software represents a cost-effective strategy to maximize the value of existing intellectual property.
The Evolution of Pharmaceutical Strategy
The traditional pharmaceutical model relies heavily on the "blockbuster" strategy, which prioritizes large-scale drug development with broad indications. While effective in the 20th century, this approach is increasingly hampered by high attrition rates in Phase II and Phase III clinical trials. According to data from the Tufts Center for the Study of Drug Development, only about 10% of drugs that enter human clinical trials eventually receive FDA approval.
In this context, companies like Remepy are positioning themselves at the intersection of pharmacology and digital health. The logic is compelling: if a patient is prescribed a medication for a chronic condition—such as diabetes, hypertension, or neurological disorders—the drug’s success depends largely on adherence, dosage timing, and lifestyle factors. By layering a software platform over the drug regimen, providers can improve outcomes without the regulatory and financial burden of developing an entirely new chemical entity.
Chronology of Digital Integration in Pharma
The integration of software into the clinical pathway did not happen overnight. It is the result of a decade-long evolution in mobile health and data science:
- 2010–2015: The "Mobile Health" (mHealth) era begins, focused primarily on fitness tracking and simple medication reminders.
- 2016–2018: The FDA begins to define its stance on "Software as a Medical Device" (SaMD), establishing clear pathways for companies seeking to combine software with clinical practice.
- 2017: The FDA approves the first digital pill (Abilify MyCite), which includes an ingestible sensor that communicates with a wearable patch, marking a milestone in drug-software integration.
- 2020–2022: The global pandemic accelerates the adoption of remote patient monitoring (RPM) and telehealth, proving that digital interfaces are essential to modern care.
- 2023–Present: The industry pivots toward "Software-enabled Pharma," where the software is treated not just as a tracking tool, but as a therapeutic component designed to enhance the biological impact of the drug.
Supporting Data: The Cost of Non-Adherence
A critical driver for this shift is the staggering cost of medication non-adherence. Research published in the Annals of Internal Medicine suggests that non-adherence to medication leads to approximately 125,000 deaths annually in the United States and accounts for roughly 10% of hospitalizations. The financial burden is equally significant, with estimates placing the annual cost of suboptimal medication use at over $100 billion in the U.S. healthcare system.
For pharmaceutical companies, these figures represent a massive loss in potential therapeutic impact and revenue. When a patient stops taking a drug due to side effects, confusion, or a lack of perceived progress, the drug is effectively a failure. By using software to engage the patient, monitor their progress in real-time, and provide interventions when adherence drops, manufacturers can stabilize the drug’s performance in real-world settings.

Industry Reaction and the "Software-as-a-Drug" Paradigm
Industry analysts have noted that the "Remepy model"—leveraging software to augment existing drugs—is gaining traction among venture capital firms and strategic investors. The move is seen as a de-risking strategy. Unlike the development of a new molecular entity (NME), which involves high risk of clinical failure, software enhancements can be iterated upon, tested through rapid clinical pilots, and scaled across existing patient populations.
However, the transition is not without challenges. Regulatory bodies like the FDA and EMA (European Medicines Agency) require rigorous evidence that software interventions actually produce clinical improvements. Critics point out that "digital noise"—the abundance of health apps—can overwhelm patients, and that integration with Electronic Health Records (EHR) remains a significant technical hurdle.
Despite these obstacles, the potential for "digitally enhanced" medicine is immense. If a patient with a chronic autoimmune condition uses a software interface that monitors stress levels, sleep, and physical activity alongside a biologic drug, the combination could theoretically yield better results than the drug alone. This is the "symphony" of care that Shoval and his peers are advocating for—moving away from a siloed approach to a holistic, data-driven therapeutic experience.
Broader Impact and Future Implications
The implications of this shift are wide-ranging. First, it forces a change in the pharmaceutical business model. Companies may eventually move toward "value-based pricing," where the cost of a drug is tied to the clinical outcomes achieved through the drug-software combination. If the software ensures that the drug is used correctly, the health system saves money on hospitalizations, creating a shared value proposition for the patient, the insurer, and the manufacturer.
Second, the role of the physician is evolving. Doctors are becoming "digital orchestrators," prescribing both a chemical regimen and a digital pathway. This requires a new set of clinical competencies and a robust infrastructure for data privacy and cybersecurity, as the integration of medical data becomes more granular and constant.
Finally, the democratization of clinical data through these software platforms will likely accelerate the next generation of drug discovery. By collecting massive datasets on how patients respond to existing drugs in real-world environments, pharmaceutical companies can identify subsets of patients who respond best to specific interventions, paving the way for hyper-personalized medicine.
Conclusion
The assertion made by Or Shoval—that the next major breakthrough will come from making existing drugs more effective through software—reflects a broader realization within the medical community. The "low-hanging fruit" of chemical discovery is increasingly difficult to reach, and the cost of bringing new, complex molecules to market is creating an unsustainable economic environment.
By focusing on the "last mile" of care—the actual interaction between the patient and the prescribed therapy—innovators are finding that software is the key to unlocking the full potential of current medicine. Whether through AI-driven adherence prompts, digital biomarkers, or behavioral cognitive tools, the software layer is poised to become a standard component of the pharmaceutical prescription. As the industry moves forward, the success of companies like Remepy will serve as a bellwether for whether this digital-first approach can fundamentally alter the trajectory of patient outcomes and redefine the value of the pharmaceutical industry in the 21st century.



